Data on PolyMedix's Novel Antibiotics Presented at the 40th Annual Meeting of the Ocular Microbiology and Immunology Group
Posted on: Monday, 13 November 2006, 09:01 CST
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced today that pre-clinical data on the potential uses of the company's compounds for ophthalmic infections were presented at the 40th Annual Meeting of the Ocular Microbiology and Immunology Group in Las Vegas, Nevada.
Drs. Eric G. Romanowski, Regis P. Kowalski, Francis S. Mah, and Y. Jerold Gordon of the Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, at the University of Pittsburgh presented preclinical data demonstrating positive results in potential treatment of bacterial eye infections with PolyMedix's novel biomimetics compounds. Their presentation entitled The in vitro Activity of Three Novel Biomimetics (PMX30006, PMX30016, PMX70004) Against Clinically Relevant Ocular Pathogens will be available on the PolyMedix website at www.polymedix.com.
"We are pleased to note that this is the first peer reviewed scientific presentation on the potential ophthalmic uses of PolyMedix's novel antibiotic compounds. The positive results obtained with our compounds in the pre-clinical setting are encouraging. Ocular infections are a serious and growing medical concern. We look forward to be able to work with the researchers at the Campbell laboratory to continue the development our compounds for ophthalmic antibiotic applications," commented Dr. Richard Scott, Vice President of Research at PolyMedix.
About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company's antibiotic compounds -- small molecule mimetics of human host-defense proteins - are believed to have a completely different mechanism of action from all current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as broad-spectrum, rapid-acting antibiotics for serious systemic and local infections. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's anticoagulant antagonist compounds reverse the activity of both heparin and low molecular weight heparins, in keeping with our goal of developing an antagonist drug that is safer and easier to use than current approved therapy. PolyMedix plans to file two INDs and start human clinical trials for its first antibiotic drug and its anticoagulant antagonist in 2007. For more information, please visit PolyMedix on its website at www.polymedix.com.
This press release contains forward-looking statements that involve risks and that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates,""believes,""hopes,""estimates,""looks,""expects,""plans,""intends" and similar expressions. Among other things, there can be no assurance that PolyMedix's compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission, including those described under the heading "Risk Factors" in the Registration Statement on Form 10-SB originally filed by PolyMedix with the Securities and Exchange Commission on April 5, 2006. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Source: Business Wire
Related Articles
- Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
- Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
- Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
- PolyMedix Presents Data on Anti-Tuberculosis Activity of Its Novel Antibiotic Compounds
- Aethlon Medical Reports Promising Treatment Results In Hepatitis-C Infected Patients
- MediciNova Reports Positive Phase IIa Clinical Study Results for MN-221, a Novel Treatment for Status Asthmaticus; Conference Call Scheduled for Today At 10:00 A.M., Eastern Time
- Metabasis Therapeutics Presents Preclinical Results for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia at the American Thyroid Association's National Meeting
- Bernanke Says Fed Policy Must Be Forward-looking
- Westinghouse Lauds Progress Energy for Proactive, Forward-Looking Approach to Nuclear Fleet Expansion
- Osmotics Corporation Licenses Worldwide Exclusive Rights From BYU for Novel Compounds That Treat Antibiotic-Resistant Infections
 |
 |
User Comments (0)
RSS Feeds